XORTX Therapeutics Files March 2025 6-K with Annual Info
Ticker: XRTX · Form: 6-K · Filed: Apr 1, 2025 · CIK: 1729214
Sentiment: neutral
Topics: corporate-filing, annual-information-form, pharmaceuticals
TL;DR
XORTX filed its March 6-K, including 2024 annual info. Check it out.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on April 1, 2025, reporting for the month of March 2025. The filing includes their Annual Information Form for the year ended December 31, 2024, along with CEO and CFO certificates. The company is based in Vancouver, Canada, and operates in the Pharmaceutical Preparations sector.
Why It Matters
This filing provides an update on XORTX Therapeutics' corporate information and annual performance, which is crucial for investors to assess the company's ongoing operations and financial standing.
Risk Assessment
Risk Level: low — This is a routine filing providing corporate information and annual data, not indicating any immediate operational or financial distress.
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Registrant
- Allen Davidoff (person) — Chief Executive Officer
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report for the month of March 2025 and to include the registrant's Annual Information Form for the fiscal year ended December 31, 2024, along with CEO and CFO certificates.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed with the SEC on April 1, 2025.
What is XORTX Therapeutics Inc.'s fiscal year end?
XORTX Therapeutics Inc.'s fiscal year end is December 31.
Who signed this report on behalf of XORTX Therapeutics Inc.?
Allen Davidoff, Chief Executive Officer, signed this report on behalf of XORTX Therapeutics Inc.
What exhibits are included with this Form 6-K?
This Form 6-K includes Exhibit 99.1 (Annual Information Form for the year ended December 31, 2024), Exhibit 99.2 (CEO Certificate), and Exhibit 99.3 (CFO Certificate).
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 1, 2025 by Allen Davidoff regarding XORTX Therapeutics Inc. (XRTX).